{"summary": "cases of severe fever with thrombocytopenia syndrome (SFTS) have risen rapidly in china, japan, and korea. from 2011 to 2016, this emerging tick-borne virus infected 5,360 people in china with an average case fatality rate of 6.40%[2] from 2011 to 2016, this emerging tick-borne virus infected 5,360 people in china. phylogenetic analysis based on genome sequences of SFTSV isolates found substantial genetic diversity and accumulated mutations. the difference in virulence between these SFTSV sub-lineages has yet to be determined. major clinical features of SFTS include high fever (body temperature 38\u00b0C), fatigue, malaise, anorexia, nausea, vomiting, diarrhea, thrombocytopenia, leukocytopenia, and abdominal pain. in animal models, however, the protective effect of human convalescent sera was shown, suggesting that antibody therapy is possible. so far, MAb4-5 is the only human neutralizing monoclonal antibody reported. phage-displayed single-chain variable fragment (scFv) antibody library was subjected to four rounds of biopanning against either the recombinant Gn-Fc or the Gc-Fc fusion proteins conjugated to paramagnetic beads. we identified five clones reactive to Gn and five clones reactive to Gc. the VH sequences of Ab10 had a 95.9% shared identity with the IGHV3-30*18 germline. the V sequence had 86.3% shared identity with the IGKV1-39*01 germline. only 5.6 2.8% of vero cells produced Gn glycoprotein when ab10 was administered at a concentration of 50 g/mL (956 nM) the proportion of infected cells compared to non-treated cells was defined as relative cell infection (%) and was plotted. asterisks indicate a statistically significant difference as determined by a nonparametric Friedman test. eight-week-old mice were inoculated with 2 or 20 PFU of SFTSV. at 1, 24, 48, and 72 h post-infection, infected mice were intraperitoneally administered with 600 g of gG1 isotope control antibody. percentages of survival (B) and body weight relative to the day of virus inoculation (C) were monitored daily until 10 days post-infection. all mice survived when treatments with ab10 were delayed until 3 d.p.i. 80% survived when the treatments were delayed until 4 or 5 d.p.i. mice with treatment delayed until 1 d.p.i. did not lose weight, whereas mice with treatment delayed until 3 d.p.i. or later, all the mice died. strains HB29, AH15, SD4, and YG1 each belong to different clusters. we overexpressed Gn glycoprotein from HB29 and SD4 as a Fc fusion protein. antibody bound to the HB29 and SD4 Gn glycoproteins coated on the ELISA plate was higher than that of Gangwon/Korea/2012 strains. surface plasmon analysis of ab10 antibody was performed on the CM5 chip with an immobilized anti-histidine antibody binding to a poly-histidine tagged SFTSV Gn ectodomain. the experimental data at concentrations of 80, 40, 20, 10, 5, 2.5, and 1.25 nM Ab10 antibody are shown in color. the conformational epitope of Ab10 antibody on the Gn glycoprotein ectodomain was determined by measuring antibody binding activity to recombinant mutant proteins with amino acid residues that were substituted with alanine at residues corresponding to 315\u2013389. the overlapping domain II (blue annotation) and region upstream of the stem region are also indicated. alanine replacement of the amino acid residues in domain II resulted in reduced relative reactivity of Ab10 by more than 60%, except for S317, G319, and M321. in the stem region, replacing the cystine residues (C349, C356, C376, and C381) reduced the relative reactivity by more than 80%. human immunoglobulin (Ig) heavy chain constant region (Gn-C and Gc-C) or those fused with the human Ig kappa light chain constant region (Gn-C and Gc-C) and then purified the proteins by affinity chromatography. the phage-displayed single-chain variable fragment (scFv) antibody library with a complexity of 1.3 109 colony forming units. the percentage of cells showing CPE was reduced from 90% to 10%. the VH sequences of Ab10 had a 95.9% shared identity with the IGHV3-30*18 germline. the V sequence had 86.3% shared identity with the IGKV1-39*01 germline (S3 Fig). antibody was used as a quantitative indicator for viral infection. proportion of infected cells compared to non-treated cells was defined as relative cell infection. mice were intraperitoneally administered with either phosphate-buffered saline (PBS), Ab10, MAb4-5, or a human IgG1 isotope control antibody at a dose of 600 g (approximately corresponding to 30 mg/kg of body weight) for 4 days at 24 h intervals, the injection of the same amount of antibody was performed. the antibody treatment started from 1, 3, 4, or 5 d.p.i. at a 2 PFU viral dose, all mice survived when treatments with Ab10 were delayed until 3 d.p.i. 80% survived when the treatments were delayed until 4 or 5 d.p.i. mice not treated until 4 d.p.i. had significant weight loss. we overexpressed and purified recombinant Gn glycoproteins of other SFTSV strains. Binding of Ab10 to intact virus particles was also confirmed using an ELISA with a virus-coated microtiter plate. surface plasmon analysis of ab10 antibody was performed on the CM5 chip with an immobilized anti-histidine antibody binding to a poly-histidine tagged SFTSV Gn ectodomain. the experimental data at concentrations of 80, 40, 20, 10, 5, 5, 2.5, and 1.25 nM ab10 antibody are shown in color. the conformational epitope of Ab10 antibody on the Gn glycoprotein ectodomain was determined by measuring antibody binding activity to recombinant mutant proteins with amino acid residues that were substituted with alanine at residues corresponding to 315\u2013389. overlapping domain II and region upstream of the stem region are also indicated. the signals detected by capturing the HA peptide were used to normalize expression of mutant proteins. alanine replacement of the amino acid residues in domain II resulted in reduced relative reactivity of Ab10 by more than 60%, except for S317, G319, and M321. polysera from recovered patients or from vaccinated donors have been used as prophylactic agents for various viral diseases. antibodies targeting emerging or re-emerging viruses including MERS-CoV[44\u201346] and Zika virus[47\u201349] have also been developed and tested as therapies or as prophylaxis for viral diseases. a study inoculated mice with 2 105 PFU of the Gangwon/Korea/2012 strain showed a similar fatality rate in STAT2 knockout hamsters challenged with 10 PFU of the HB29 strain. this increased virulence was also reported by a study that showed a similar fatality rate in STAT2 knockout Syrian hamsters challenged with 10 PFU of the HB29 strain. the epitope was confined to domain II and the stem region of the Gn glycoprotein. a recent report showed a cryo-electron microscopy map of RVFV. it also describes the membrane fusion mechanism of RVFV that is mediated by a low pH exposure of the hydrophobic fusion loop. all animal studies were conducted in an Animal Biosafety Level 3 (ABSL-3) facility at the Institut Pasteur Korea. all experimental procedures were reviewed and approved by the Institutional Animal Care and Use Committee at the Institut Pasteur Korea. cloned into modified pCEP4 vector with a leader sequence of the human immunoglobulin kappa chain, two Sfil restriction enzyme sites, and the Fc region of human IGHG1 or human immunoglobulin kappa constant region. overexpressed recombinant SFTSV Gn and Gc glycoprotein fusion proteins were purified by affinity chromatography using MabSelect or KappaSelect columns. the whole protein, designated as Gn-Fc-HA, was produced as described above. a Gn-C with six carboxy-terminal poly-histidine residues was designed and produced. cDNA was synthesized using a superscript III first-strand cDNA synthesis kit with oligo dT priming. genes encoding the scFv-Fc fusion protein and the scFv-C fusion protein were synthesized and cloned into a pCEP4 vector. expression vectors were transfected into HEK 293F cells. the recombinant proteins were overexpressed and purified. 10 or MAB4-5 scFv-Fc fusion protein was serially diluted in 10-fold increments from a 50 g/mL concentration. then mixed with 100 TCID50 SFTSV and incubated at 37\u00b0C for 1 h. for the infection-control group, no antibody was incubated with the virus. cells were inoculated onto monolayers of Vero cells in 6-well tissue culture plates for 1 h at room temperature. cells were washed three times with PBS and incubated with dulbecco\u2019s Modified Eagle\u2019s Medium (12100\u2013046; Gibco) based overlay medium containing 0.7% agar. plates were blocked with 3% skim milk in PBS for 1 h at room temperature. plates were then washed with PBS and received antibodies that were serially diluted from 1 M to 10 M in blocking buffer. each well received 50 L of 3,3\u2032,5,5\u2032-tetramethylbenzidine (TMB) substrate solution. antibody/antigen complexes were characterized by high mass matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. a proteolytic buffer composed of trypsin, chymotrypsin, endoproteinase Asp-N, elastase, and thermolysin was used. ELISA for epitope mapping To measure binding activities of Ab10 to mutated Gn, ab10 scFv-C antibody and an anti-influenza virus hemagglutinin antibody (clone 12CA5; Bio X Cell, NH, USA) were coated on a microplate, in parallel. plates were blocked with 3% skim milk in PBS for 1 h at room temperature. fluorescent signals measured by confocal microscopy were quantified using Leica Application Suite Advanced Fluorescence software. Plasmon surface resonance data were analyzed using BIAevaluation software. human codon optimized DNA sequence of SFTSV Gc ectodomain of strain Gangwon/Korea/2012 was also synthesized. overexpressed recombinant recombinant SFTSV Gn and Gc glycoprotein fusion proteins were purified by affinity chromatography using MabS. alanine-scanning mutagenesis, SFTSV Gn glycoprotein with amino acid residues (315\u2013389) substituted with alanine were produced by cloning synthesized DNA fragments into a modified pCEP4 vector. a ligand for surface plasmon resonance analysis, a Gn-C with six carboxy-terminal poly-histidine residues was designed and produced as described above. recombinant SFTSV Gn-Fc coated onto paramagnetic Dynabeads. phage ELISA was performed using Gn or Gc glycoprotein-coated microtiter plates. nucleotide sequences of positive scFv clones were determined by Sanger nucleotide sequencing. expression vectors were transfected into HEK 293F cells. the virus-antibody mixture was transferred onto vero cells in 8-well chamber slides. cells were incubated at 37\u00b0C for 1 h. no antibody was incubated with virus. FITC-conjugated anti-rabbit IgG Fc antibody was used to stain the nucleus. fluorescence image of cells was monitored under a confocal laser scanning microscope. titer of SFTSV was measured by plaque forming assays[69] infected mice were treated with antibodies at 1, 3, 4, or 5 days post-infection. body weight and survival of mice were monitored until 10 days post-infection. 96-well half-area microplates were coated with 3% skim milk. anti-histidine antibody was immobilized on an activated CM5 chip, followed by a deactivation step. for the association step, all of the ab10 IgG1 antibody in PBS at concentrations of two-fold increments ranging from 1.25 nM to 80 nM was injected for 3 min. after each dissociation step, chip regeneration was performed. a proteolytic buffer composed of trypsin, chymotrypsin, endoproteinase Asp-N, elastase, and thermolysin was used to digest the reduced complex. each well received 50 L of 3,3\u2032,5,5\u2032-tetramethylbenzidine (TMB) substrate solution. the color reaction was stopped by adding 50 L of 2 M sulfur. the absorbance of each well was measured at 450 nm using a microplate spectrophotometer (Multiskan GO; Thermo Scientific) data analysis ELISA and IFA data including statistical comparisons were analyzed and graphed using GraphPad Prism software. in the control groups, cells not incubated with virus (Uninfected), cells infected without antibody treatment (Infected), cells infected with virus, and the isotype control antibody (Isotype control antibody) were employed. the percentage of neutralization was calculated for each diluted solution of antibody. dose-response curves were drawn by non-linear regression analyses. 50% FRNT values were determined from graphs using GraphPad Prism6 software. the amount of virus coated on each microplate well is indicated on the top of each graph. absorption of ab10 antibody bound to SFTSV-coated wells (red), Palivizumab bound to mock-virus coated wells (blue), and Palivizumab bound to mock-virus coated wells (purple) are shown in the graph. the samples were separated on a polyacrylamide gel (NP0321BOX; Invitrogen) by electrophoresis and transferred to a nitrocellulose membrane. the membrane was incubated with 100 ng/mL of five (Ab6 to Ab10) SFTSV antibodies. if)"}